An Observational Study of Avastin (Bevacizumab) in First Line in Patients With Metastatic Colorectal Cancer (AVANiS)

Non-interventional Study of Avastin in 1st Line Metastatic Colorectal Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01674907

Enrollment

Registered

2012-08-29

Start date

2010-03-31

Completion date

2012-04-30

Last updated

2016-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

This observational study will evaluate the use in clinical practice and the efficacy of Avastin (bevacizumab) in patients with metastatic colorectal cancer who have not received prior chemotherapy treatment in the metastatic setting. Patients for whom the treating physician has decided to initiate therapy with Avastin will be followed for 10 months.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients, \>/= 18 years of age * Histologically confirmed metastatic colorectal cancer without prior chemotherapy in the metastatic setting

Exclusion criteria

* Contraindications for Avastin according to the locally approved package insert (version 7 April 2006)

Design outcomes

Primary

Measure	Time frame
Dosage/schedule of 1st-line Avastin	approximately 3 years
Duration of treatment	approximately 3 years
Chemotherapy regimens used in clinical practice	approximately 3 years
Clinical/demographic patient characteristics at baseline	approximately 3 years

Secondary

Measure	Time frame
Progression-free survival	approximately 3 years
Relationship between termination of Avastin treatment and time point of progression	approximately 3 years

Countries

South Africa

Outcome results